Skip to ContentSkip to Navigation
About us Practical matters How to find us dr. A.J. van der Wekken

Publications

A Drug–Drug Interaction Study of Mobocertinib and Midazolam, a Cytochrome P450 3A Substrate, in Patients With Advanced Non–Small Cell Lung Cancer

Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer

Presence of On-Target Resistant Mutation in Pre-Treatment Samples of ALK Fusion Gene Positive Lung Cancer Patients

An Evidence-Based Rationale for Dose De-escalation of Subcutaneous Atezolizumab

A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer

AUTHOR CORRECTION to: “Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer” (ERJ Open Res 2022; 8: 00239-2022)

Baseline Blood CD8+ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer

Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations

Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer

Press/media

Door chemotekorten worden minder effectieve behandelingen ingezet

Stand van Nederland - Wereld op Scherp: Een bittere pil (WNL NPO2)

RTV Noord Vandaag

Effect van pil tegen longkanker

Pil tegen longkanker 'halveert kans op overlijden' voor kleine groep patiënten

Hoop voor kleine groep longkankerpatiënten: pil per dag halveert kans op overlijden

Doelgerichte therapie bij longkanker

Actionabiliteit van on-target ALK-resistentiemutaties in niet-kleincellig longcarcinoom

Longkanker: welke vorm heb ik?